LB-102
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- LB-102
- Molecular weight
- 383.51
- Structure (SMILES)
- CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)c(NC)cc1OC
- lb 102
- Lb-102
- LB-102
- LB-102 (100 mg tablet)
- LB-102 (50 mg tablet)
- lb102
- LB102
- n methyl amisulpride
- n methylamisulpride
- N'-methyl amisulpride
- N'-methylamisulpride
- CAS registry numbers
- 2227154-23-4
- ChEMBL ID
- CHEMBL4594422
- InChIKey
- NXKXZXNNWRYXRE-UHFFFAOYSA-N
- PubChem compound IDs
- 134542980
- FDA ingredient codes (UNII)
- N81WKW91XF
- First in class
- No
- Orphan designation
- No
Investigated indications
- Condition
- Schizophrenia
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0005090
- Subject identifier
- D012559
- Condition identifier
- EFO_0007634
- Highest recorded phase
- 2
- Condition identifier
- EFO_0009963
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005090
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005090
- Highest recorded phase
- 3
- NCT04187560
- NCT04588129
- NCT06179108
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 2
- Polar surface area
- 87.74
- Calculated partition coefficient (ALogP)
- 1.74
- Calculated partition coefficient (XLogP)
- 2.1
- Prodrug
- No
- Chirality
- Racemic
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 8
- Heavy atoms
- 26
- Molecular formula
- C18H29N3O4S
- Monoisotopic mass
- 383.18787759
- Natural product
- No
- Recorded assays
- 4
- Active assays
- 4
Active assay types
- Confirmatory
Related records
Trials (448)
- 52-week Open Label Safety-Tolerability Study
- A Bioavailability Study Comparing 3 Different AZD1981 Tablets
- A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial
- A Clinical Intervention Study of Tangningtongluo on Diabetic Foot Ulcer
- A Clinical Study Comparing the Bioavailability of HRS-2189 Tablets
- A Clinical Study of HRS-5765 in Healthy Participants
- A Clinical Study of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects
- A Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Uncomplicated Acute Influenza
- A Clinical Study to Assess the Safety and Effectiveness of Herbal Supplement in Adult Human Subjects.
- A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis
- A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects
- A Clinical Study to Evaluate the Long-term Safety of HRS-1893 in Hypertrophic Cardiomyopathy
- A Clinical Study to Explore Biomarkers for Drug-induced Liver Injury (DILI)
- A Clinical Trial for Azvudine in the Treatment of Novel Coronavirus Pneumonia (COVID-19）
- A Clinical Trial of HRS-3095 in Patients With Chronic Spontaneous Urticaria
- A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies
- A Clinical Trial of XZP-6019 Tablets in Healthy Subjects
- A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .
- A Clinical Trial to Assess Three Different Doses of OPS-2071 in Patients With Bacterial Enteritis
- A Comparative Pharmacokinetic Study of Single-Dose Administration of HR091506 Tablets From Different Batches in Healthy Subjects
In development for (1)
- Schizophrenia Phase 2